A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Frontal Fibrosing Alopecia, sponsored by LEO Pharma. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 216 studies in Alopecia with a site in United States, this one is the 117th largest by enrollment of the 203 interventional ones that give a count, is one of 17 that started in 2022, is one of 47 in phase 2, and was the 136th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
K. Kay Durairaj, MD, FACS, A Medical Corporation · Sites in United States
Ages 35–55 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
216 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 57 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 17 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 203 interventional studies, 204 across the 12 observational. Of the 126 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
123 of 216 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
LEO Pharma has 1 study filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 216 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions. The trial also investigated the clinical effect of delgocitinib cream on FFA compared to a placebo cream.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Group 1 only (subjects with FFA):
For Group 2 only (healthy subjects):
Exclusion criteria
For all subjects:
For Group 1 only (subjects with FFA):
For Group 2 only (healthy subjects):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were blinded and randomised to delgocitinib cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
Drug: Delgocitinib cream
Participants were blinded and randomised to placebo cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
Drug: Delgocitinib cream · Drug: Delgocitinib cream vehicle
Participants did not receive any treatment. They only provided a molecular signature of healthy skin to act as a control.
Cream for topical application
Also known as: LEO 124249 cream
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12.
CXCL9, CXCL10 and IFN-γ are small proteins that act as chemical messengers, especially in the immune system.
Time frame: Baseline and Week 12
Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12.
Treatment emergent adverse events (TEAEs) were defined as any AEs with onset date on or after the first study treatment dosing.
Time frame: Between baseline and Week 12
The trial was conducted in the United States and consisted of 2 cohorts: Cohort 1 included 30 subjects with FFA and Cohort 2 included 5 healthy postmenopausal female subjects. Both cohorts were conducted in parallel.
| Milestone | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment |
|---|---|---|---|
| Started | 15 | 15 | 5 |
| Completed | 15 | 15 | 5 |
| Not completed | 0 | 0 | 0 |
CXCL9, CXCL10 and IFN-γ are small proteins that act as chemical messengers, especially in the immune system.
| Fold-changes | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment |
|---|---|---|---|
| (C-X-C motif) ligand 9 (CXCL9) | -3.10 | -1.12 | — |
| Chemokine (C-X-C motif) ligand 10 (CXCL10) | -2.60 | -1.10 | — |
| Interferon (IFN)-γ | -1.49 | -1.097 | — |
Treatment emergent adverse events (TEAEs) were defined as any AEs with onset date on or after the first study treatment dosing.
| events | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment |
|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) From Baseline to Week 12. | 4 | 9 | — |
Collected over Baseline and week 12. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delgocitinib - Delgocitinib | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Placebo - Delgocitinib | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| No Treatment | — | — | — |
| Event | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment |
|---|---|---|---|
| COVID-19Infections and infestations | 1/15 | 7/15 | — |
| PainGeneral disorders | 1/15 | 0/15 | — |
| PneumoniaInfections and infestations | 0/15 | 1/15 | — |
| Upper respiratory tract infectionInfections and infestations | 0/15 | 1/15 | — |
| Arthropod biteInjury, poisoning and procedural complications | 1/15 | 0/15 | — |
| Incision site rashInjury, poisoning and procedural complications | 1/15 | 0/15 | — |
| Procedural painInjury, poisoning and procedural complications | 1/15 | 0/15 | — |
| Antinuclear antibody positiveInvestigations | 0/15 | 1/15 | — |
| HyperlipidaemiaMetabolism and nutrition disorders | 0/15 | 1/15 | — |
| HyponatraemiaMetabolism and nutrition disorders | 1/15 | 0/15 | — |
| Age, Continuous(years) | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment | Total |
|---|---|---|---|---|
| Mean | 66.2 ± 6.82 | 62.6 ± 12.64 | 67.4 ± 9.81 | 64.8 ± 10.0 |
| Sex: Female, Male(Participants) | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment | Total |
|---|---|---|---|---|
| Female | 15 | 15 | 5 | 35 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 2 |
| Not Hispanic or Latino | 13 | 15 | 5 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 14 | 15 | 5 | 34 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment | Total |
|---|---|---|---|---|
| United States | 15 | 15 | 5 | 35 |
| Height (cm)(units on a scale) | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment | Total |
|---|---|---|---|---|
| Mean | 163.34 ± 7.557 | 162.49 ± 6.970 | 165.20 ± 8.415 | 163.24 ± 7.257 |
| Weight (kg)(units on a scale) | Delgocitinib - Delgocitinib | Placebo - Delgocitinib | No Treatment | Total |
|---|---|---|---|---|
| Mean | 68.41 ± 15.245 | 75.41 ± 16.503 | 72.40 ± 17.418 | 71.98 ± 15.950 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Feb 2023, 9 months.
Results were first posted in Feb 2025, 1 year 11 months after primary completion. A results delay was requested in Feb 2024.
Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 9 months is below that.
Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib